MedTrace Logo

Development of NIC5-15 in the Treatment of Alzheimer's Disease

NCT00470418 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-01-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.

Conditions

Interventions

DRUG

NIC5-15

a natural product, found in many foods and plants with mild insulin sensitizing effects

DRUG

Placebo

placebo comparator

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Humanetics Corporation

    collaborator INDUSTRY

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Hillel Grossman, MD · VA Medical Center, Bronx

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-08-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00470418 on ClinicalTrials.gov